Mga Batayang Estadistika
| LEI | 5299006K52ZIIGQJ6R84 |
| CIK | 1176309 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Oramed Pharmaceuticals Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 19, 2025 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 21, 2025 |
As filed with the Securities and Exchange Commission on August 21, 2025 As filed with the Securities and Exchange Commission on August 21, 2025 Registration No. |
|
| August 21, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Oramed Pharmaceuticals Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common st |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as S |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 22, 2025 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 23, 2025 |
Exhibit 10.1 Execution Version Certain information in this document (indicated by [***]) has been excluded pursuant to Regulation S-K Item 601(b)(10). Such information is not material and is treated by the Registrant as private or confidential. July 22, 2025 Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Option Agreement for the Repurchase of Warrants |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2) ☒ Defin |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2025 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 15, 2025 |
Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made effective as of April 1, 2025, by and between Oramed Pharmaceuticals Inc., a company incorporated under the laws of the State of Delaware, with an address at 20 Mamilla Ave., Jerusalem, Israel 9414904 (the “Company”) and KNRY Ltd., a company incorporated under the laws of the State of Israel, (company I.D. no. 5 |
|
| May 15, 2025 |
Exhibit 10.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is dated as of April 24, 2025, between Alpha Tau Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to |
|
| May 15, 2025 |
Employment Agreement by and between Oramed Ltd. and Miriam Kidron, entered into as of April 1, 2025 Exhibit 10.3 Employment Agreement This Employment Agreement is made effective as of the 1st day of April 2025, by and between Miriam Kidron, an individual residing in Jerusalem, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at 20 Mamilla Ave., Jerusalem, Israel (the “Company”). WHEREAS, the Company has agreed to engage the |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as |
|
| April 28, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2025 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 28, 2025 |
Exhibit 10.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is dated as of April 24, 2025, between Alpha Tau Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to |
|
| April 28, 2025 |
Exhibit 99.1 Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts |
|
| March 27, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the securities of Oramed Pharmaceuticals Inc. (the “Company”) is a summary only. This summary is not complete and is subject to and qualified by the provisions of the Company’s Certificate of Incorporation, as amended (the “Charter”), and By-l |
|
| March 27, 2025 |
Exhibit 21.1 SUBSIDIARIES Oramed Ltd. – Incorporated in the State of Israel Oramed HK Limited – Incorporated in Hong Kong OraTech Pharmaceuticals, Inc. – Incorporated in State of Nevada (100% owned by Oramed Pharmaceuticals Inc.) Oravax Medical Inc. – Incorporated in the State of Delaware (63% owned by Oramed Pharmaceuticals Inc.) RoyaltyVest, LTD. - Incorporated in the British Virgin Islands (50% |
|
| March 27, 2025 |
Fifth Amended and Restated By-laws, adopted effective March 27, 2025. Exhibit 3.2 ORAMED PHARMACEUTICALS INC. FOURTH AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES 1. The location of the registered office of the Corporation, and the name of its registered agent, shall be as set forth in the Certificate of Incorporation. 2. The Corporation shall in addition to its registered office in the State of Delaware establish and maintain an office or offices at such place or |
|
| March 27, 2025 |
Exhibit 10.72 Second Amendment to Consulting Agreement This Second Amendment to Consulting Agreement (this “Second Amendment”) is entered into as of November 7, 2024 and is effective as of July 1, 2024, by and between Oramed Pharmaceuticals Inc., a company incorporated under the laws of the State of Delaware, with an address at 20 Mamilla Ave., Jerusalem, Israel 9414904 (the “Company”) and Shnida |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Spe |
|
| March 27, 2025 |
Fifth Amended and Restated By-laws, adopted effective March 27, 2025 (marked copy). Exhibit 3.3 ORAMED PHARMACEUTICALS INC. FOURTH AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES 1. The location of the registered office of the Corporation, and the name of its registered agent, shall be as set forth in the Certificate of Incorporation. 2. The Corporation shall in addition to its registered office in the State of Delaware establish and maintain an office or offices at such place or |
|
| March 27, 2025 |
Exhibit 10.74 AGREEMENT AND AMENDMENT NO. 10 This AGREEMENT AND AMENDMENT NO. 10 (this “Ninth Amendment”) is made as of November 7, 2024 and is effective as of July 1, 2024, by and between Oramed Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at Mamilla, 20, Jerusalem, Israel 9414904 (the “Company”), and KNRY, Ltd., a company incorporated under the |
|
| March 27, 2025 |
Oramed Pharmaceuticals Inc. Insider Trading Policy. Exhibit 19.1 ORAMED PHARMACEUTICALS INC. INSIDER TRADING POLICY Effective: March 20, 2025 This policy sets forth guidelines for all Insiders (as defined below) of Oramed Pharmaceuticals Inc. (together with its subsidiaries when the context so requires, “Oramed”) with respect to transactions in Oramed securities. This policy arises from Oramed’s responsibilities as a public company whose shares of |
|
| March 27, 2025 |
Exhibit 10.73 Second Amendment to Employment Agreement This Second Amendment to Employment Agreement (this “Second Amendment”) is entered into as of November 7, 2024 and is effective as of July 1, 2024, by and between Nadav Kidron, an individual residing in Jerusalem, Israel (the “Executive”), and Oramed Ltd., a company incorporated under the laws of the State of Israel, with an address at 20 Mami |
|
| March 3, 2025 |
Exhibit 10.3 SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of February 28, 2025, by and between EFSHAR HATAYA LTD, a Marshall Islands corporation, in its capacity as agent for itself and the other Royalty Secured Parties (as defined below) (together with its successors and assigns, “Royalty Agent”), and SCILEX HOLDING COMPANY, a Delaware corporation (“S |
|
| March 3, 2025 |
Exhibit 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”) is made and entered into as of February 28, 2025 by and among Scilex Holding Company, a Delaware corporation (“Scilex”) and Scilex Pharmaceuticals Inc. (collectively with Scilex, “Grantor”), Efshar Hataya Ltd, a Marshall Islands corporation (“Murchinson”), in its capacity as agent (“Agent”) for Murchinson, Oramed Pharmaceut |
|
| March 3, 2025 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2025 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35813 98-0376008 (State or other jurisdiction of incorporation) (Comm |
|
| March 3, 2025 |
Exhibit 10.4 AMENDMENT NO. 1 TO PURCHASE AND SALE AGREEMENT This AMENDMENT NO. 1 TO PURCHASE AND SALE AGREEMENT, dated as of February 28, 2025 (this “Amendment”), amends that certain PURCHASE AND SALE AGREEMENT (the “Purchase and Sale Agreement”), dated as of October 8, 2024, by and among SCILEX PHARMACEUTICALS INC., a Delaware corporation (the “Seller”), SCILEX HOLDING COMPANY, a Delaware corpora |
|
| March 3, 2025 |
Exhibit 10.5 GLOPERBA LICENSE AGREEMENT dated as of February 28, 2025 by and between SCILEX HOLDING COMPANY, SCILEX PHARMACEUTICALS INC., as the Licensor Parties and ROYALTYVEST LTD. as Licensee ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION 1 Section 1.1 Defined Terms 1 Section 1.2 Rules of Construction 8 ARTICLE II REPRESENTATIONS AND WARRANTIES 10 Section 2.1 Mutual Representation and Warran |
|
| March 3, 2025 |
Exhibit 10.1 PURCHASE AND SALE AGREEMENT dated as of February 28, 2025 by and among SCILEX HOLDING COMPANY, SCILEX PHARMACEUTICALS INC., as the Seller Parties and EFSHAR HATAYA LTD, ORAMED PHARMACEUTICALS INC., and 3I, LP as the Purchasers ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION 1 Section 1.1 Defined Terms 1 Section 1.2 Rules of Construction 11 ARTICLE II PURCHASE AND SALE OF THE PURCHAS |
|
| February 27, 2025 |
Exhibit 10.1 LIDOCAINE LICENSE AGREEMENT dated as of February 22, 2025 by and between SCILEX PHARMACEUTICALS INC. as Licensor and ROYALTYVEST LTD. as Licensee ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION 1 Section 1.1 Defined Terms 1 Section 1.2 Rules of Construction 9 ARTICLE II REPRESENTATIONS AND WARRANTIES 10 Section 2.1 Mutual Representation and Warranties 10 Section 2.2 Licensor Represe |
|
| February 27, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2025 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35813 98-0376008 (State or other jurisdiction of incorporation) (Comm |
|
| February 27, 2025 |
Exhibit 10.2 Page 1 February 22, 2025 Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL Re: Parent Guarantee for Lidocaine License Agreement (this “Side Letter”) Ladies and Gentlemen: Reference is made to that Lidocaine License Agreement, dated as of February 22, 2025 (the “License Agreement”), between Scilex Pharmaceuticals, Inc. (“Licensor”) and RoyaltyVe |
|
| February 11, 2025 |
Exhibit 10.6 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. Execution Version Novation Agreement and Release This Novation Agreement and Release (this “Agreement”), is made effective as of February 7, 2025 (the “Effective Date”), by |
|
| February 11, 2025 |
Exhibit 10.3 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. ASSET TRANSFER AGREEMENT This Asset Transfer Agreement (this “Agreement”) is entered into as of February 7, 2025 (the “Effective Date”), by and among: a. Oramed Pharmaceutic |
|
| February 11, 2025 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of [], 2025 by and among: (a) Oramed NewCo, Inc., a corporation duly organized and existing under the laws of the State of Nevada with Nevada Business Identification number NV20243151449 with its principal office at 716 N. Carson t. #B, Carson City, NV 89701 (c/o Capitol Co |
|
| February 11, 2025 |
Exhibit 10.5 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT This License Agreement (this “Agreement”) is entered into as of February 7, 2025 (the “Effective Date”), by and among: a. Hefei Tianhui Biotech Co., Ltd., |
|
| February 11, 2025 |
Exhibit 10.1 Final Version ANCILLARY AGREEMENT COMPLETION PROTOCOL AND SUPPLEMENTAL AGREEMENT This Ancillary Agreement Completion Protocol and Supplemental Agreement (this “Agreement”) is entered into as of February 7, 2025 (the “Effective Date”) by and among (a) Hefei Tianhui Biotech Co., Ltd., a limited liability company incorporated and existing under the laws of the People’s Republic of China |
|
| February 11, 2025 |
Exhibit 99.1 Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities · Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq. · OraTech will have |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 7, 2025 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 11, 2025 |
Exhibit 10.4 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. Execution Version SUPPLY AGREEMENT This Supply Agreement (the “Agreement”) is entered into as of February 7, 2025 (the “Effective Date”), by and among: (a) Hefei Tianhui Bio |
|
| January 22, 2025 |
Exhibit 10.1 January 21, 2025 SCLX Stock Acquisition JV 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Xiao Xu And Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Amendment to Senior Secured Promissory Note (this “Amendment”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchase Agreement, dated as of September 21, 2023 (the “S |
|
| January 22, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 21, 2025 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 3, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 2, 2025 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 3, 2025 |
Exhibit 10.1 Execution Version January 2, 2025 SCLX Stock Acquisition JV 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Xiao Xu Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Deferral and Consent under Tranche B Senior Secured Convertible Note (this “Consent Letter”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchase Agreem |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 24, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 8, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 7, 2024, is by and among Scilex Holding Company, a Delaware corporation with offices located at 960 San Antonio Road, Palo Alto, CA 94303 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyer |
|
| October 8, 2024 |
Exhibit 10.9 SUBSIDIARY GUARANTEE AMENDMENT THIS AMENDMENT (this “Amendment”) to that certain Subsidiary Guarantee, dated as of September 21, 2023 (the “Guarantee”), made by Scilex Holding Company, a Delaware corporation (the “Company”) and the Guarantors (as defined in the Guarantee) in favor of the holders of that certain Senior Secured Promissory Note dated as of September 21, 2023 due March 21 |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 8, 2024 (October 7, 2024) ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Inco |
|
| October 8, 2024 |
Exhibit 10.10 AMENDED AND RESTATED SECURITY AGREEMENT This AMENDED AND RESTATED SECURITY AGREEMENT, dated as of October 8, 2024 (this “Agreement”), is among Scilex Holding Company, a Delaware corporation (the “Company”), the Subsidiaries of the Company party hereto (such subsidiaries, the “Grantors” and together with the Company, the “Debtors”) and Acquiom Agency Services LLC, a Colorado limited l |
|
| October 8, 2024 |
Exhibit 10.6 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”) is made and entered into as of October 8, 2024 by and among Scilex Pharmaceuticals Inc., a Delaware corporation (“Grantor”), Efshar Hataya Ltd, a Marshall Islands corporation (“Murchinson”), in its capacity as agent (“Agent”) for Murchinson, Oramed Pharmaceuticals Inc., a Delaware corporation (“Oramed”) and 3i, LP, a Delawa |
|
| October 8, 2024 |
Exhibit 10.3 TRANCHE B SENIOR SECURED CONVERTIBLE NOTE THE PRINCIPAL AMOUNT REPRESENTED BY THIS NOTE AND, ACCORDINGLY, THE SECURITIES ISSUABLE UPON CONVERSION HEREOF MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 3(c)(iii) OF THIS NOTE. THIS NOTE HAS BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT (“OID”). PURSUANT TO TREASURY REGULATION §1.1275-3(b)(1), STEPHEN MA, A REPRE |
|
| October 8, 2024 |
Exhibit 10.2 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This AMENDMENT NO. 1, dated as of October 8, 2024 (this “Amendment”), to the SECURITIES PURCHASE AGREEMENT, is by and among Scilex Holding Company, a Delaware corporation with offices located at 960 San Antonio Road, Palo Alto, CA 94303 (the “Company”), Oramed Pharmaceuticals Inc. (the “Investor”) and Acquiom Agency Services LLC as the |
|
| October 8, 2024 |
Exhibit 10.11 Rest of World License Term Sheet Pursuant to this binding term sheet (“Term Sheet”), Lido Dev Co (as defined below) , Scilex Holdings Company (along with its affiliates, including, without limitation Silex Pharmaceuticals Inc., “SHC”), each a “party” and collectively, the “parties”, for good and adequate consideration, the receipt, sufficiency and adequacy of which is hereby acknowle |
|
| October 8, 2024 |
Exhibit 10.12 AGREEMENT AMONG HOLDERS AGREEMENT AMONG HOLDERS, dated as of October 8, 2024 (as amended, restated or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), among (a) each Tranche A Holder executing this Agreement as a First Out Holder (as defined below) on the signature pages hereto, (b) each Tranche B Holder executing this Agreement as a Last O |
|
| October 8, 2024 |
Exhibit 10.4 WARRANT THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. Scilex Holding Company Warrant To Purchase Common Stock Warrant No.: 4 Date of Issuance: October 8, 2024 (“Issuance Date”) Scilex Holding Company, a Delaware corporation (the “Company”), hereby certifies |
|
| October 8, 2024 |
Exhibit 10.5 PURCHASE AND SALE AGREEMENT dated as of October 8, 2024 by and among SCILEX HOLDING COMPANY, SCILEX PHARMACEUTICALS INC., as the Seller Parties and efshar hataya ltd, ORAMED PHARMACEUTICALS INC., and 3i, LP as the Purchasers ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION 1 Section 1.1 Defined Terms 1 Section 1.2 Rules of Construction 11 ARTICLE II PURCHASE AND SALE OF THE PURCHASED |
|
| October 8, 2024 |
Exhibit 10.7 SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of October 8, 2024, by and between Efshar Hataya Ltd, a Marshall Islands corporation, in its capacity as agent for itself and the other Royalty Secured Parties (as defined below) (together with its successors and assigns, “Royalty Agent”), and SCILEX PHARMACEUTICALS INC., a Delaware corporation |
|
| October 8, 2024 |
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt Exhibit 99.1 Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt NEW YORK, October 7, 2024 - Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (“Oramed”), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the execution of definitive agreements for the restructuring of a portion of its existing Senior Secured |
|
| October 8, 2024 |
Exhibit 10.8 October 8, 2024 Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Consent and Amendment under Senior Secured Promissory Note (this “Consent and Amendment”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchase Agreement, dated as of September 21, 2023 (the “SPA”), among Scilex Holding Company, a Delaware corporation |
|
| September 26, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 26, 2024 |
Exhibit 10.1 MASTER SERVICES AGREEMENT This Master Services Agreement (this “Agreement”), entered into as of September 23, 2024, is by and between InClin, Inc., a California Corporation located at 155 Bovet Road, Ste 660, San Mateo CA 94402 (“CRO”) and Oramed Ltd. with offices located at 20 Mamilla Ave., 3rd Floor Jerusalem, Israel 9414904 (“Sponsor”). Sponsor has solicited the services of CRO, an |
|
| September 23, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2024 (September 20, 2024) ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction o |
|
| September 23, 2024 |
Exhibit 10.1 September 20, 2024 Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Consent under Senior Secured Promissory Note (this “Consent Letter”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchase Agreement, dated as of September 21, 2023 (the “SPA”), among Scilex Holding Company, a Delaware corporation (the “Company”), |
|
| September 16, 2024 |
ORMP / Oramed Pharmaceuticals Inc. / BML Investment Partners, L.P. Passive Investment SC 13G 1 ormp13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* Oramed Pharmaceuticals, Inc. (Name of Issuer) Common Stock par value $0.012 per share (Title of Class of Securities) 68403P203 (CUSIP |
|
| August 14, 2024 |
Employment Agreement, dated June 6, 2024, between Oramed Ltd. and Avraham Gabay. Exhibit 10.2 Employment Agreement This Employment Agreement is made on 6 day of June 2024, by and between Avraham Gabay, an individual residing in Petakh Tikva, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at Mamila 20, Jerusalem, Israel (the “Company”). WHEREAS, the Company has agreed to engage the Executive to serve in t |
|
| August 14, 2024 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or officers unless they are provided with adequate protection through insurance or adequ |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as S |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 26, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2) ☒ Defin |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) (IR |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) (IR |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as |
|
| May 9, 2024 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or officers unless they are provided with adequate protection through insurance or adequ |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 22, 2024 |
ORMP / Oramed Pharmaceuticals Inc. / KIDRON NADAV - SCHEDULE 13D Activist Investment SC 13D 1 ea0202287-13dkidronoramed.htm SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Oramed Pharmaceuticals Inc. (Name of Issuer) Common Stock par value $0.012 per share (Titl |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 18, 2024 |
Exhibit 1.1 Oramed Pharmaceuticals Inc. Shares of Common Stock (par value $0.012 per share) AT THE MARKET OFFERING AGREEMENT March 18, 2024 Rodman & Renshaw LLC 600 Lexington Avenue, 32nd Floor New York, NY 10022 StockBlock Securities LLC 600 Lexington Avenue, 32nd Floor New York, New York 10022 Ladies and Gentlemen: Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), confirms its |
|
| March 18, 2024 |
Up to $75,000,000 COMMON STOCK Filed Pursuant to Rule 424(b)(5) Registration No. 333-257926 PROSPECTUS SUPPLEMENT (to prospectus dated July 26, 2021) Up to $75,000,000 COMMON STOCK Oramed Pharmaceuticals Inc. has entered into an at the market offering agreement, dated March 18, 2024, or the ATM Agreement, with Rodman & Renshaw LLC (“Rodman”) and StockBlock Securities LLC (“StockBlock”), each referred to as an Agent and together |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) ( |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employer |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Spe |
|
| March 6, 2024 |
Exhibit 10.2 First Amendment to Consulting Agreement This First Amendment to Consulting Agreement (this “First Amendment”) is entered into as of April 27, 2023 and is effective as of April 17, 2023, by and between Oramed Pharmaceuticals Inc., a company incorporated under the laws of the State of Delaware, with an address at 20 Mamilla Ave., Jerusalem, Israel 9414904 (the “Company”) and Shnida Ltd. |
|
| March 6, 2024 |
Exhibit 10.21 Fourth Amendment to Employment Agreement This Fourth Amendment to Employment Agreement (this “Fourth Amendment”) is entered into as of this 8th day of January 2024 and is effective as of January 1, 2024, by and between David Silberman, an individual residing in Jerusalem, Israel (the “Executive”), and Oramed Ltd., a company incorporated under the laws of the State of Israel, with an |
|
| March 6, 2024 |
Exhibit 10.6 Second Amendment to Employment Agreement This Second Amendment to Employment Agreement (this “Second Amendment”) is entered into as of January 8, 2024 and is effective as of January 1, 2024, by and between Nadav Kidron, an individual residing in Jerusalem, Israel (the “Executive”), and Oramed Ltd., a company incorporated under the laws of the State of Israel, with an address at 20 Mam |
|
| March 6, 2024 |
Exhibit 10.5 First Amendment to Employment Agreement This First Amendment to Employment Agreement (this “First Amendment”) is entered into as of April 27, 2023 and is effective as of April 17, 2023, by and between Nadav Kidron, an individual residing in Jerusalem, Israel (the “Executive”), and Oramed Ltd., a company incorporated under the laws of the State of Israel, with an address at 20 Mamilla |
|
| March 6, 2024 |
Exhibit 10.3 Second Amendment to Consulting Agreement This Second Amendment to Consulting Agreement (this “Second Amendment”) is entered into as of January 8, 2024 and is effective as of January 1, 2024, by and between Oramed Pharmaceuticals Inc., a company incorporated under the laws of the State of Delaware, with an address at 20 Mamilla Ave., Jerusalem, Israel 9414904 (the “Company”) and Shnida |
|
| March 6, 2024 |
Oramed Pharmaceuticals Inc. Clawback Policy, adopted November 9, 2023 Exhibit 97.1 ORAMED PHARMACEUTICALS INC. (the “Company”) CLAWBACK POLICY Effective: November 9, 2023 Background The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s compensation philosophy. The Board has therefo |
|
| March 6, 2024 |
Exhibit 10.15 AGREEMENT AND AMENDMENT NO. 8 This AGREEMENT AND AMENDMENT NO. 8 (this “Eighth Amendment”) is made as of April 27, 2023 and is effective as of April 17, 2023, by and between Oramed Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at Mamilla, 20, Jerusalem, Israel 9414904 (the “Company”), and KNRY, Ltd., a company incorporated under the l |
|
| March 6, 2024 |
Exhibit 10.22 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or officers unless they are provided with adequate protection through insurance or adeq |
|
| March 6, 2024 |
Exhibit 10.20 Third Amendment to Employment Agreement This Third Amendment to Employment Agreement (this “Third Amendment”) is entered into as of April 27, 2023 and is effective as of April 17, 2023, by and between David Silberman, an individual residing in Jerusalem, Israel (the “Executive”), and Oramed Ltd., a company incorporated under the laws of the State of Israel, with an address at 20 Mami |
|
| March 6, 2024 |
Exhibit 10.16 AGREEMENT AND AMENDMENT NO. 9 This AGREEMENT AND AMENDMENT NO. 9 (this “Ninth Amendment”) is made as of January 8, 2024 and is effective as of January 1, 2024, by and between Oramed Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at Mamilla, 20, Jerusalem, Israel 9414904 (the “Company”), and KNRY, Ltd., a company incorporated under the |
|
| February 20, 2024 |
Exhibit 99.1 Oramed Letter to Shareholders · Initiating Phase 3 oral insulin trial in the United States under a new protocol · JV with Chinese Partner, HTIT · Scilex Senior Secured Note · PeriTech Asset Purchase & Strategic Out-licensing NEW YORK, February 20, 2024 – Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development |
|
| February 20, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 23, 2024 |
Exhibit 10.1 JOINT VENTURE AGREEMENT This Joint Venture Agreement (this “Agreement”) is entered into as of 22 January 2024 by and among (a) Hefei Tianhui Biotech Co., Ltd., a limited liability company incorporated and existing under the laws of the People’s Republic of China and registered with its registered address at No. 199 Fanhua Road Hefei Economic & Technological Development Area, Hefei, An |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 17, 2024 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2023 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 18, 2023 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant |
|
| September 26, 2023 |
Exhibit 10.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 21, 2023 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Numbe |
|
| September 26, 2023 |
Exhibit 10.8 NUMBER - (SEE REVERSE SIDE FOR LEGEND) THIS WARRANT WILL BE VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION DATE (DEFINED BELOW) WARRANTS VICKERS VANTAGE CORP. I CUSIP G9440B 115 WARRANT THIS CERTIFIES THAT, for value received is the registered holder of a warrant or warrants (the “Warrant”) of Vickers Vantage Corp. I, a Cayman Islands exempted company (the “Company”), expiring at 5:00 |
|
| September 26, 2023 |
Exhibit 10.9 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 21, 2023, between Scilex Holding Company, a Delaware corporation (the “Company”), and Oramed Pharmaceuticals, Inc. (“Purchaser”). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and Purchaser |
|
| September 26, 2023 |
Exhibit 10.5 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| September 26, 2023 |
Exhibit 10.11 EXECUTION VERSION SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of September 21, 2023 (this “Agreement”), is among Scilex Holding Company, a Delaware corporation (the “Company”), the Subsidiaries of the Company party hereto (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) and Acquiom Agency Services LLC, a Colorado limited liability company, a |
|
| September 26, 2023 |
Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 21, 2023, between Scilex Holding Company, a Delaware corporation (the “Company”), Oramed Pharmaceuticals, Inc., a Delaware corporation as the initial purchaser (the “Initial Purchaser”), and the Agent. WHEREAS, subject to the terms and conditions set forth in |
|
| September 26, 2023 |
Exhibit 10.10 EXECUTION VERSION SUBSIDIARY GUARANTEE SUBSIDIARY GUARANTEE, dated as of September 21, 2023 (this “Guarantee”), made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “Guarantors”) in favor of the holders of that certain Senior Secured Promissory Note dated as of the date hereof due March 21, 2025 in the original |
|
| September 26, 2023 |
Exhibit 10.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| September 26, 2023 |
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company Exhibit 99.1 Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company ● 18-month loan with interest rate of SOFR plus 8.5% ● Oramed receives warrants to purchase up to 17 million shares of Scilex common stock ● The Senior Secured Note with Scilex replaces Oramed’s previously announced Stock Purchase Agreement and DIP Term Loan with Sorrento Therapeutics |
|
| September 26, 2023 |
Exhibit 10.7 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| September 26, 2023 |
Exhibit 10.2 EXECUTION VERSION THIS SENIOR SECURED PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED |
|
| September 26, 2023 |
Exhibit 10.12 Execution Version MUTUAL TERMINATION AND RELEASE AGREEMENT This Mutual Termination and Release Agreement (this “Agreement”) is entered into as of September 21, 2023, by and between Sorrento Therapeutics, Inc., a Delaware corporation, (“Sorrento”), and Oramed Pharmaceuticals, Inc., a Delaware corporation (“Oramed”, and together with Sorrento, the “Parties”). WHEREAS, on February 13, 2 |
|
| September 26, 2023 |
EX-10.6 7 ea185680ex10-6oramedpharma.htm WARRANT NO. ORMP CS-4 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY Exhibit 10.6 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE |
|
| September 13, 2023 |
NON-BINDING TERM SHEET September 11, 2023 Exhibit 99.1 Execution Version NON-BINDING TERM SHEET September 11, 2023 The following non-binding term sheet (“Term Sheet”) outlines, in addition to the other matters described herein, the proposed terms of (A) the declaration of Scilex as the winning bidder for the purchase of the Securities Transfer (as defined below) pursuant to the Winning Bid (as defined below), and either (B) the closing of |
|
| September 13, 2023 |
TERM SHEET FOR SENIOR SECURED NOTE AND WARRANTS AND RELATED MATTERS September 11, 2023 Exhibit 99.2 EXECUTION TERM SHEET FOR SENIOR SECURED NOTE AND WARRANTS AND RELATED MATTERS September 11, 2023 PARTIES Company: Scilex Holding Company, a Delaware corporation (the “Company” or “SCLX”). Investor: Oramed Pharmaceuticals, Inc. (the “Investor” or “Oramed”). Sorrento: Sorrento Therapeutics Inc., a Delaware corporation (“Sorrento”). NON-BINDING TERMS Securities: In exchange for the consu |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 11, 2023 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Numbe |
|
| August 22, 2023 |
Exhibit 2.3 SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT THIS SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT (this “Amendment”) is made as of August 21, 2023, by and between Sorrento Therapeutics, Inc., a Delaware corporation (the “Seller”), and Oramed Pharmaceuticals Inc., a Delaware corporation (the “Purchaser”). Capitalized terms used herein without definition shall have the meaning ascribed to s |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 17, 2023 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) |
|
| August 10, 2023 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or officers unless they are provided with adequate protection through insurance or adequ |
|
| August 10, 2023 |
Exhibit 2.2 FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT THIS FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT (this “Amendment”) is made as of August 9, 2023, by and between Sorrento Therapeutics, Inc., a Delaware corporation (the “Seller”), and Oramed Pharmaceuticals Inc., a Delaware corporation (the “Purchaser”). Capitalized terms used herein without definition shall have the meaning ascribed to such |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as S |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2023 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) ( |
|
| August 9, 2023 |
Exhibit 10.1 Execution Version SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION LOAN AND SECURITY AGREEMENT by and among SORRENTO THERAPEUTICS, INC. SCINTILLA PHARMACEUTICALS, INC. as Borrowers, and Oramed Pharmaceuticals Inc., as Lender Dated as of August 9, 2023 TABLE OF CONTENTS Page 1. DEFINITIONS AND CONSTRUCTION. 2 1.1 Definitions 2 1.2 Accounting Terms 13 1.3 UCC 13 1.4 Construction 13 1 |
|
| August 9, 2023 |
Exhibit 2.1 Execution Version CONFIDENTIAL STOCK PURCHASE AGREEMENT BETWEEN ORAMED PHARMACEUTICALS INC. AND SORRENTO THERAPEUTICS, INC. August 7, 2023 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT is made and entered into as of August 7, 2023 (this “Agreement”), between Oramed Pharmaceuticals Inc., a Delaware corporation (“Purchaser”), on the one hand, and Sorrento Therapeutics, Inc., a D |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2023 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) ( |
|
| August 7, 2023 |
Stalking Horse Stock Purchase Term Sheet Exhibit 99.1 Execution Version Stalking Horse Stock Purchase Term Sheet This term sheet (this “Stalking Horse Term Sheet”) sets forth the principal terms of a proposed equity sale transaction (the “Sale”) between the parties described herein. Consummation of the Sale is subject to (i) final definitive documentation to be negotiated in good faith between the parties, (ii) the satisfaction or waiver |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2023 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2) ☒ Defin |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2023 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 6, 2023 |
Exhibit 10.13 Second Amendment to Employment Agreement This Second Amendment to Employment Agreement (this “Second Amendment”) is entered into as of this 25th day of October 2022 and is effective as of January 1, 2023, by and between David Silberman, an individual residing in Jerusalem, Israel (the “Executive”), and Oramed Ltd., a company incorporated under the laws of the State of Israel, with an |
|
| March 6, 2023 |
Form of Restricted Stock Unit Notice and Restricted Stock Unit Agreement. Exhibit 10.23 ORAMED PHARMACEUTICALS INC. AMENDED AND RESTATED 2019 STOCK INCENTIVE PLAN Restricted Stock Unit Notice Grantee Name and Address: In accordance with and subject to the Restricted Stock Unit Agreement, of which this Restricted Stock Unit Notice is a part (which together, constitute the “Customizing Information”), the Company hereby grants to the above named grantee (the “Grantee”) the |
|
| March 6, 2023 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the securities of Oramed Pharmaceuticals Inc. (the “Company”) is a summary only. This summary is not complete and is subject to and qualified by the provisions of the Company’s Certificate of Incorporation, as amended (the “Charter”), and By-l |
|
| March 6, 2023 |
EX-10.42 9 f10k2022ex10-42oramedpharma.htm ORAVAX STOCK OPTION AGREEMENT Exhibit 10.42 STOCK OPTION AGREEMENT ORAVAX MEDICAL, INC. 2021 LONG-TERM INCENTIVE PLAN 1. Grant of Option. Pursuant to the Oravax Medical, Inc. 2021 Long-Term Incentive Plan (the “Plan”) for Employees, Contractors, and Outside Directors of Oravax Medical, Inc., a Delaware corporation (the “Company”), the Company grants to (t |
|
| March 6, 2023 |
Exhibit 10.2 Employment Agreement This Employment Agreement is made effective as of the 1st day of November 2022, by and between Nadav Kidron, an individual residing in Jerusalem, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at 20 Mamilla Ave., Jerusalem, Israel (the “Company”). WHEREAS, the Company has agreed to engage th |
|
| March 6, 2023 |
Exhibit 10.14 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or officers unless they are provided with adequate protection through insurance or adeq |
|
| March 6, 2023 |
Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made effective as of November 1, 2022, by and between Oramed Pharmaceuticals Inc., a company incorporated under the laws of the State of Delaware, with an address at 20 Mamilla Ave., Jerusalem, Israel 9414904 (the “Company”) and Shnida Ltd., a company incorporated under the laws of the State of Israel, (company I.D. |
|
| March 6, 2023 |
Exhibit 10.41 ORAVAX MEDICAL, INC. 2021 LONG-TERM INCENTIVE PLAN The Oravax Medical, Inc. 2021 Long-Term Incentive Plan (the “Plan”) was adopted by the Board of Directors of Oravax Medical, Inc., a Delaware corporation (the “Company”), effective as of , 2021 (the “Effective Date”), subject to approval by the Company’s stockholders. Article 1. PURPOSE The purpose of the Plan is to attract and retai |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Spe |
|
| February 27, 2023 |
Exhibit 3.2 ORAMED PHARMACEUTICALS INC. THIRDFOURTH AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES 1. The location of the registered office of the Corporation is 1013 Centre Road, Suite 403-B, in the City of Wilmington, County of New Castle, Delaware 19805, and the name of its registered agent at such address is Vcorp Services, LLC, shall be as set forth in the Certificate of Incorporation. 2. The |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number |
|
| February 27, 2023 |
Exhibit 3.1 ORAMED PHARMACEUTICALS INC. FOURTH AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES 1. The location of the registered office of the Corporation, and the name of its registered agent, shall be as set forth in the Certificate of Incorporation. 2. The Corporation shall in addition to its registered office in the State of Delaware establish and maintain an office or offices at such place or |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2023 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employe |
|
| December 12, 2022 |
Exhibit 99.1 Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations December 2022 Oramed Pharmaceuticals Inc. ? 2022 Safe Harbor 1 Oramed Pharmaceuticals Inc. ? 2022 This presentation contains forward - looking statements. For example, we are using forward - looking statements when we discuss clinical trials, including the timing thereof and potential approvals of prod |
|
| December 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2022 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2022 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant |
|
| November 10, 2022 |
Oramed Reports Third Quarter 2022 Financial Results Exhibit 99.1 Oramed Reports Third Quarter 2022 Financial Results NEW YORK, November 10, 2022 ? Oramed Pharmaceuticals Inc. (?Oramed? or the ?Company?) (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today reported its financial results for the quarter ended September 30, 2022. "We are pleased to share our qua |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission?File Number |
|
| September 19, 2022 |
Third Amended and Restated By-laws, adopted effective September 15, 2022. (Filed herewith). Exhibit 3.1 ORAMED PHARMACEUTICALS INC. THIRD AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES 1. The location of the registered office of the Corporation is 1013 Centre Road, Suite 403-B, in the City of Wilmington, County of New Castle, Delaware 19805, and the name of its registered agent at such address is Vcorp Services, LLC. 2. The Corporation shall in addition to its registered office in the St |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 15, 2022 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| September 19, 2022 |
Exhibit 3.2 ORAMED PHARMACEUTICALS INC. SECOND THIRD AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES 1. The location of the registered office of the Corporation is 1811 Silverside 1013 Centre Road, Suite 403-B, in the City of Wilmington, County of New Castle, Delaware 19810 19805, and the name of its registered agent at such address is Vcorp Services, LLC. 2. The Corporation shall in addition to it |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2022 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 1, 2022 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as S |
|
| July 12, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Oramed Pharmaceuticals Inc. |
|
| July 12, 2022 |
As filed with the Securities and Exchange Commission on July 12, 2022 As filed with the Securities and Exchange Commission on July 12, 2022 Registration No. |
|
| July 7, 2022 |
Exhibit 99.1 Oramed Letter to Shareholders ? $169 Million in Cash and Investments ? Pivotal Phase 3 Oral Insulin Data Expected January 2023 ? Phase 2 NASH Data Expected This Quarter ? Oravax - Oral Vaccine NEW YORK, July 7, 2022 ? Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, tod |
|
| July 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 7, 2022 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) (IR |
|
| June 30, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2022 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| June 2, 2022 |
DEF 14A 1 ea160778-def14aoramed.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as |
|
| May 12, 2022 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of August 30, 2016 between Oramed Pharmaceuticals Inc., a Delaware corporation (the ?Company?), and Kevin Rakin (?Indemnitee?). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or officers unless they are provided with adequate protectio |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2022 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employer |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☐ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended ☒ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from September 1, 2021 to December 31, 2021 Commission file number: 001-35813 OR |
|
| February 28, 2022 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2022 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employ |
|
| January 12, 2022 |
Oramed Issues Annual Message to Shareholders Exhibit 99.1 Oramed Issues Annual Message to Shareholders ? Oral insulin program continues to advance with topline efficacy data expected in H2 2022 ? Significant value creation opportunities through oral COVID-19 vaccine program and partnerships ? Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3, 2021 NEW YORK, January 12, 2022 ? Oramed Pha |
|
| January 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 12, 2022 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) |
|
| January 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 7, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) |
|
| December 7, 2021 |
Exhibit 99.1 Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations December 2021 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the management of Oramed only, including with respect to clinical trials, milestones and the potential benefits of Ora |
|
| December 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 7, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) delaware 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) |
|
| November 24, 2021 |
Exhibit 21.1 SUBSIDIARIES Oramed Ltd. ? Incorporated in the State of Israel Oramed HK Limited ? Incorporated in Hong Kong Oravax Medical Inc. ? Incorporated in the State of Delaware (63% owned by Oramed Pharmaceuticals Inc.) |
|
| November 24, 2021 |
Exhibit 10.7 AGREEMENT AND AMENDMENT NO. 6 This AGREEMENT AND AMENDMENT NO. 7 (this ?Sixth Amendment?) is made this 19th day of September, 2021 by and between Oramed Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at Mamilla, 20, Jerusalem, Israel 9414904 (the ?Company?), and KNRY, Ltd., a company incorporated under the laws of the State of Israel, # |
|
| November 24, 2021 |
Exhibit 10.31 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of August 30, 2016 between Oramed Pharmaceuticals Inc., a Delaware corporation (the ?Company?), and Kevin Rakin (?Indemnitee?). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or officers unless they are provided with adequate protecti |
|
| November 24, 2021 |
Employment Agreement, dated July 25, 2021, by and between the Company and Michael Rabinowitz. Exhibit 10.24 Employment Agreement This Employment Agreement is made on 25 day of July 2021, by and between, Michael Rabinowitz an individual residing in Pennsylvania, United States (the ?Executive?), and ORAMED PHARMACEUTICALS, INC., a company incorporated under the laws of the State of Delaware, (the ?Company?). WHEREAS, the Company has agreed to engage the Executive to serve in the role of Chie |
|
| November 24, 2021 |
Exhibit 10.33 First Amendment to Employment Agreement This First Amendment to Employment Agreement (this ?First Amendment?) is entered into as of this 19th day of September 2021 and is effective as of September 1, 2021, by and between Joshua Hexter, an individual residing in Jerusalem, Israel (the ?Executive?), and Oramed Ltd., a company incorporated under the laws of the State of Israel, with an |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended August 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Speci |
|
| November 24, 2021 |
Exhibit 10.26 First Amendment to Employment Agreement This First Amendment to Employment Agreement (this ?First Amendment?) is entered into as of this 19th day of September 2021 and is effective as of September 1, 2021, by and between David Silberman, an individual residing in Jerusalem, Israel (the ?Executive?), and Oramed Ltd., a company incorporated under the laws of the State of Israel, with a |
|
| November 24, 2021 |
Exhibit 10.14 AGREEMENT AND AMENDMENT NO. 7 This AGREEMENT AND AMENDMENT NO. 7 (this ?Seventh Amendment?) is made this 19th day of September, 2021 by and between Oramed Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at Mamilla, 20, Jerusalem, Israel 9414904 (the ?Company?), and KNRY, Ltd., a company incorporated under the laws of the State of Israel |
|
| November 4, 2021 |
Engagement Letter, dated as of November 2, 2021, between the Company and H.C. Wainwright & Co., LLC. EX-1.1 2 ea149991ex1-1oramed.htm ENGAGEMENT LETTER, DATED AS OF NOVEMBER 2, 2021, BETWEEN THE COMPANY AND H.C. WAINWRIGHT & CO., LLC Exhibit 1.1 Execution Version November 2, 2021 STRICTLY CONFIDENTIAL Nadav Kidron, Esq. Chief Executive Officer, President & Director Oramed Pharmaceuticals Inc. 1185 Avenue of the Americas, Third Floor New York, NY 10036 Dear Mr. Kidron: This letter agreement (this |
|
| November 4, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of [?], 2021, between Oramed Pharmaceuticals Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions |
|
| November 4, 2021 |
2,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-257926 PROSPECTUS SUPPLEMENT (to prospectus dated July 26, 2021) 2,000,000 Shares of Common Stock We are offering 2,000,000 shares of our common stock, par value $0.012 per share, at a price of $25.00 per share of common stock, to certain institutional and accredited investors pursuant to this prospectus supplement and the accompanying prospect |
|
| November 4, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 ea149991-8koramed.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) |
|
| September 2, 2021 |
SC 13D/A 1 ea146876-13da5kidronoramed.htm AMENDMENT NO. 5 TO SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) Oramed Pharmaceuticals Inc. (Name of Issuer) Common Stock par value $0.012 per share (Title of Class of Securities) 68403P203 (CUSIP Number) Nadav Kidron c/o Oramed Pharmaceutica |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employer |
|
| September 1, 2021 |
Exhibit 1.1 Oramed Pharmaceuticals Inc. Shares of Common Stock (par value $0.012 per share) Controlled Equity OfferingSM September 1, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Oramed Pharmaceuticals Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (?Cantor?), as of the date first written |
|
| September 1, 2021 |
Up to $100,000,000 COMMON STOCK Filed Pursuant to Rule 424(b)(5) Registration No. 333-257926 PROSPECTUS SUPPLEMENT (to prospectus dated July 26, 2021) Up to $100,000,000 COMMON STOCK Oramed Pharmaceuticals Inc. has entered into an equity distribution agreement, dated September 1, 2021, or the equity distribution agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock offered by this |
|
| August 31, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employer |
|
| August 13, 2021 |
Up to 3,007,680 SHARES OF COMMON STOCK As Filed Pursuant to Rule 424(b)(7) Registration No. 333-252696 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated February 10, 2021) Up to 3,007,680 SHARES OF COMMON STOCK This prospectus supplement supplements information contained in the prospectus dated February 10, 2021 covering the resale of shares of our common stock by selling stockholders as described therein. This prospectus supplement is |
|
| August 5, 2021 |
Exhibit 99.1 Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations August 2021 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the management of Oramed only, including with respect to clinical trials, milestones and the potential benefits of Orame |
|
| August 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employer |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) (I |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the Appropriate Box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| July 22, 2021 |
July 22, 2021 VIA EDGAR Christine Westbrook Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the Appropriate Box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| July 15, 2021 |
Exhibit 3.1 ORAMED PHARMACEUTICALS INC. SECOND AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES 1. The location of the registered office of the Corporation is 1811 Silverside Road, in the City of Wilmington, County of New Castle, Delaware 19810, and the name of its registered agent at such address is Vcorp Services, LLC. 2. The Corporation shall in addition to its registered office in the State of D |
|
| July 15, 2021 |
Exhibit 3.2 ORAMED PHARMACEUTICALS INC. SECOND AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES 1. The location of the registered office of the Corporation is 1811 Silverside Road, in the City of Wilmington, County of New Castle, Delaware 19810, and the name of its registered agent at such address is Vcorp Services, LLC. 2. The Corporation shall in addition to its registered office in the State of D |
|
| July 15, 2021 |
As filed with the Securities and Exchange Commission on July 15, 2021 As filed with the Securities and Exchange Commission on July 15, 2021 Registration No. |
|
| July 15, 2021 |
Exhibit 1.1 ORAMED PHARMACEUTICALS INC. $100,000,000 equity distribution AGREEMENT July 15, 2021 Canaccord Genuity LLC 99 High Street, Suite 1200 Boston, Massachusetts 02110 Ladies and Gentlemen: Oramed Pharmaceuticals Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Canaccord Genuity LLC (?Canaccord?), as of the date first written above, as follows: The |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-50298 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Sp |
|
| July 14, 2021 |
Exhibit 10.1 Employment Agreement This Employment Agreement is made on 23 day of May 2021, by and between David Silberman, an individual residing in Jerusalem, Israel (the ?Executive?), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at Mamila 20, Jerusalem, Israel (the ?Company?). WHEREAS, the Company has agreed to engage the Executive to serve in th |
|
| July 14, 2021 |
Exhibit 10.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of August 30, 2016 between Oramed Pharmaceuticals Inc., a Delaware corporation (the ?Company?), and Kevin Rakin (?Indemnitee?). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or officers unless they are provided with adequate protectio |
|
| June 16, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-236194 and 333-257128 PROSPECTUS SUPPLEMENT (to prospectus dated February 10, 2020) $28,000,000 Common Stock Oramed Pharmaceuticals Inc. has entered into an equity distribution agreement, dated June 16, 2021, or the equity distribution agreement, with Canaccord Genuity LLC, or Canaccord Genuity, relating to shares of our common stock offered by |
|
| June 16, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 ea142779-8koramedpharma.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State |
|
| June 16, 2021 |
Exhibit 1.1 ORAMED PHARMACEUTICALS INC. $28,000,000 equity distribution AGREEMENT June 16, 2021 Canaccord Genuity LLC 99 High Street, Suite 1200 Boston, Massachusetts 02110 Ladies and Gentlemen: Oramed Pharmaceuticals Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Canaccord Genuity LLC (?Canaccord?), as of the date first written above, as follows: The |
|
| June 16, 2021 |
As filed with the Securities and Exchange Commission on June 16, 2021 As filed with the Securities and Exchange Commission on June 16, 2021 Registration No. |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) (IR |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| April 13, 2021 |
Exhibit 10.1 Second Amendment to Employment Agreement This Second Amendment to Employment Agreement (this ?Second Amendment?) is entered into as of this February 8, 2021 and is effective as of January 1, 2021, by and between Avraham Gabay, an individual residing in Jerusalem, Israel (the ?Executive?), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at |
|
| April 13, 2021 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-50298 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) ( |
|
| March 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) ( |
|
| March 19, 2021 |
Exhibit 99.1 Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations March 2021 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the management of Oramed only, including with respect to clinical trials, milestones and the potential benefits of Oramed |
|
| March 19, 2021 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ORAMED PHARMACEUTICALS INC. IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS WITH ASTERISKS THROUGHOUT THIS EXHIBIT. LICENSE AGREEMENT This License Agreement (?Agreement?), effective as of March 18, 2021 (the ?Effective Date?), |
|
| March 19, 2021 |
Exhibit 10.2 STOCKHOLDERS AGREEMENT THIS STOCKHOLDERS AGREEMENT (this ?Agreement?), is made and entered into as of this 18th day of March, 2021, by and among Oravax Medical Inc., a Delaware corporation (the ?Company?) and those certain stockholders of the Company listed on Schedule A (together with any subsequent stockholders or holders of options to acquire shares of the capital stock of the Comp |
|
| February 9, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ORAMED PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.012 per share (Title of Class of Securities) 68403P203 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 9, 2021 |
February 9, 2021 VIA EDGAR Ada D. Sarmento Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Oramed Pharmaceuticals Inc. Registration Statement on Form S-3 File No. 333-252696 Dear Sir or Madam: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Oramed Pharmaceuticals Inc. (the ?Registrant?) hereby requests |
|
| February 9, 2021 |
Agreement of Joint Filing. (Filed herewith) CUSIP No. 68403P203 13G/A Page 10 of 10 Pages Exhibit 99.1 AGREEMENT OF JOINT FILING The undersigned hereby agree that the Schedule 13G with respect to the shares of common stock, $0.012 par value per share, of Oramed Pharmaceuticals Inc., dated as of February 9, 2021, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accord |
|
| February 4, 2021 |
Regulation FD Disclosure - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2021 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission File Number) |
|
| February 3, 2021 |
As filed with the Securities and Exchange Commission on February 3, 2021 Registration No. |
|
| January 14, 2021 |
Quarterly Report - QUARTERLY REPORT 10-Q 1 f10q1120oramedpharma.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-50298 ORAME |
|
| December 2, 2020 |
8-K 1 ea130845-8koramedpharma.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 2, 2020 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (Sta |
|
| December 1, 2020 |
Exhibit 1.1 ORAMED PHARMACEUTICALS INC. $40,000,000 equity distribution AGREEMENT December 1, 2020 Canaccord Genuity LLC 99 High Street, Suite 1200 Boston, Massachusetts 02110 Ladies and Gentlemen: Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Canaccord Genuity LLC (“Canaccord”), as of the date first written above, as follows: T |
|
| December 1, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2020 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employe |
|
| December 1, 2020 |
424B5 1 ea130775-424b5oramed.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-236194 PROSPECTUS SUPPLEMENT (to prospectus dated February 10, 2020) $40,000,000 Common Stock Oramed Pharmaceuticals Inc. has entered into an equity distribution agreement, dated December 1, 2020, or the equity distribution agreement, with Canaccord Genuity LLC, or Canaccord Genuity, relati |
|
| November 24, 2020 |
EX-3.1 2 f10k2020ex3-1oramedpharma.htm COMPOSITE COPY OF CERTIFICATE OF INCORPORATION, AS AMENDED AS OF JANUARY 22, 2013, CORRECTED FEBRUARY 8, 2013, AS AMENDED AS OF JULY 25, 2014, CORRECTED SEPTEMBER 5, 2017 AND AS FURTHER AMENDED AS OF AUGUST 3, 2020 Exhibit 3.1 CERTIFICATE OF INCORPORATION OF ORAMED PHARMACEUTICALS INC. As amended as of January 22, 2013 corrected February 8, 2013 further amend |
|
| November 24, 2020 |
EX-3.2 3 f10k2020ex3-2oramedpharma.htm COMPOSITE COPY OF CERTIFICATE OF INCORPORATION, AS AMENDED AS OF JANUARY 22, 2013, CORRECTED FEBRUARY 8, 2013, AS AMENDED AS OF JULY 25, 2014, CORRECTED SEPTEMBER 5, 2017 AND AS FURTHER AMENDED AS OF AUGUST 3, 2020 Exhibit 3.2 CERTIFICATE OF INCORPORATION OF ORAMED PHARMACEUTICALS INC. As amended as of January 22, 2013 corrected February 8, 2013 further amend |
|
| November 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended August 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-50298 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Speci |
|
| November 24, 2020 |
EX-4.4 4 f10k2020ex4-4oramedpharma.htm DESCRIPTION OF SECURITIES Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the securities of Oramed Pharmaceuticals Inc. (the “Company”) is a summary only. This summary is not complete and is subject to and qualified by the provisions of the Company’s C |
|
| October 22, 2020 |
Exhibit 99.1 Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations October 2020 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the management of Oramed only, including with respect to clinical trials, milestones and the potential benefits of Oram |
|
| October 22, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 22, 2020 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employe |
|
| September 18, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2020 (September 16, 2020) ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction o |
|
| September 18, 2020 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ORAMED PHARMACEUTICALS INC. IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS WITH ASTERISKS THROUGHOUT THIS EXHIBIT. CLINICAL RESEARCH ORGANIZATION SERVICES AGREEMENT By and Between Oramed Ltd. and Integrium, LLC Effective Date: |
|
| September 9, 2020 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ORAMED PHARMACEUTICALS INC. IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS WITH ASTERISKS THROUGHOUT THIS EXHIBIT. CLINICAL RESEARCH ORGANIZATION SERVICES AGREEMENT By and Between Oramed Ltd. and Integrium, LLC Effective Date: |
|
| September 9, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2020 (September 2, 2020) ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Co |
|
| August 27, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2020 (August 21, 2020) ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commis |
|
| August 11, 2020 |
As filed with the Securities and Exchange Commission on August 11, 2020 Registration No. |
|
| August 4, 2020 |
Certificate of Amendment, dated August 3, 2020. EX-3.1 2 ea124938ex3-1oramed.htm CERTIFICATE OF AMENDMENT, DATED AUGUST 3, 2020. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ORAMED PHARMACEUTICALS INC. Oramed Pharmaceuticals Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies: FIRST: That the Certifica |
|
| August 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2020 (August 3, 2020) ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commissi |
|
| July 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2020 ORAMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) DELAWARE 001-35813 98-0376008 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| July 7, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-50298 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Sp |
